Research Reports | Market Assessment
November 2016

Heart Failure | Access and Reimbursement | Chronic Heart Failure | US | 2016

The chronic heart failure therapy market is crowded and dominated by generics. In 2015 in the United States, the first new branded agents in more than 15 years entered that market. Using primary research from U.S. cardiologists, primary care physicians, and managed care organization medical/pharmacy directors, this content examines market access factors in the United States. Understanding the interaction between payers and physicians, including the impact of reimbursement decisions on the prescribing and uptake of therapies at the brand level, will help unravel treatment drivers in this indication.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports